Cargando…
Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer
BACKGROUND: The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS: All cases of lung cancer included in our prospective database betwe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068452/ https://www.ncbi.nlm.nih.gov/pubmed/29917320 http://dx.doi.org/10.1111/1759-7714.12790 |
_version_ | 1783343272021721088 |
---|---|
author | Zhou, Haitao Kang, Xiaozheng Dai, Liang Yan, Wanpu Yang, Yongbo Lin, Yao Chen, Ke‐Neng |
author_facet | Zhou, Haitao Kang, Xiaozheng Dai, Liang Yan, Wanpu Yang, Yongbo Lin, Yao Chen, Ke‐Neng |
author_sort | Zhou, Haitao |
collection | PubMed |
description | BACKGROUND: The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS: All cases of lung cancer included in our prospective database between January 2000 and July 2015 were retrospectively reviewed. The oncological efficacy endpoints for synchronous and metachronous MPR were five‐year overall survival (OS), disease‐free survival (DFS), and progression‐free survival (PFS) rates after the second surgery. The surgical safety endpoints were postoperative mortality and complications (Clavien‐Dindo classification) within 30 days. RESULTS: In total, 67 MPR cases were identified. There were no significant differences in the five‐year OS and DFS between the synchronous MPR group (n = 50) and the propensity score‐matched solitary major pulmonary resection group (n = 250) (5‐year OS 84.5% vs. 69.0%, log rank P = 0.112; DFS 64.4% vs. 58.0%, log rank P = 0.278). The five‐year OS and PFS of the metachronous MPR group (n = 17) were significantly better than those in the non‐surgical control group (n = 19) (5‐year OS 94.1% vs. 50.7%, log rank P = 0.005; 5‐year PFS 53.9% vs. 10.5%, log rank P = 0.020). No postoperative mortality or severe complications occurred in the MPR group. CONCLUSION: The oncological efficacy of MPR is superior to the non‐surgical approach for the management of local regional recurrent or second primary lung cancer, with comparable postoperative mortality and complications. |
format | Online Article Text |
id | pubmed-6068452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60684522018-08-03 Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer Zhou, Haitao Kang, Xiaozheng Dai, Liang Yan, Wanpu Yang, Yongbo Lin, Yao Chen, Ke‐Neng Thorac Cancer Original Articles BACKGROUND: The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS: All cases of lung cancer included in our prospective database between January 2000 and July 2015 were retrospectively reviewed. The oncological efficacy endpoints for synchronous and metachronous MPR were five‐year overall survival (OS), disease‐free survival (DFS), and progression‐free survival (PFS) rates after the second surgery. The surgical safety endpoints were postoperative mortality and complications (Clavien‐Dindo classification) within 30 days. RESULTS: In total, 67 MPR cases were identified. There were no significant differences in the five‐year OS and DFS between the synchronous MPR group (n = 50) and the propensity score‐matched solitary major pulmonary resection group (n = 250) (5‐year OS 84.5% vs. 69.0%, log rank P = 0.112; DFS 64.4% vs. 58.0%, log rank P = 0.278). The five‐year OS and PFS of the metachronous MPR group (n = 17) were significantly better than those in the non‐surgical control group (n = 19) (5‐year OS 94.1% vs. 50.7%, log rank P = 0.005; 5‐year PFS 53.9% vs. 10.5%, log rank P = 0.020). No postoperative mortality or severe complications occurred in the MPR group. CONCLUSION: The oncological efficacy of MPR is superior to the non‐surgical approach for the management of local regional recurrent or second primary lung cancer, with comparable postoperative mortality and complications. John Wiley & Sons Australia, Ltd 2018-06-19 2018-08 /pmc/articles/PMC6068452/ /pubmed/29917320 http://dx.doi.org/10.1111/1759-7714.12790 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Zhou, Haitao Kang, Xiaozheng Dai, Liang Yan, Wanpu Yang, Yongbo Lin, Yao Chen, Ke‐Neng Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer |
title | Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer |
title_full | Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer |
title_fullStr | Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer |
title_full_unstemmed | Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer |
title_short | Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer |
title_sort | efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068452/ https://www.ncbi.nlm.nih.gov/pubmed/29917320 http://dx.doi.org/10.1111/1759-7714.12790 |
work_keys_str_mv | AT zhouhaitao efficacyofrepeatedsurgeryissuperiortothatofnonsurgeryforrecurrentsecondprimarylungcancerafterinitialoperationforprimarylungcancer AT kangxiaozheng efficacyofrepeatedsurgeryissuperiortothatofnonsurgeryforrecurrentsecondprimarylungcancerafterinitialoperationforprimarylungcancer AT dailiang efficacyofrepeatedsurgeryissuperiortothatofnonsurgeryforrecurrentsecondprimarylungcancerafterinitialoperationforprimarylungcancer AT yanwanpu efficacyofrepeatedsurgeryissuperiortothatofnonsurgeryforrecurrentsecondprimarylungcancerafterinitialoperationforprimarylungcancer AT yangyongbo efficacyofrepeatedsurgeryissuperiortothatofnonsurgeryforrecurrentsecondprimarylungcancerafterinitialoperationforprimarylungcancer AT linyao efficacyofrepeatedsurgeryissuperiortothatofnonsurgeryforrecurrentsecondprimarylungcancerafterinitialoperationforprimarylungcancer AT chenkeneng efficacyofrepeatedsurgeryissuperiortothatofnonsurgeryforrecurrentsecondprimarylungcancerafterinitialoperationforprimarylungcancer |